AFT Pharmaceuticals Ltd
NZX:AFT
Intrinsic Value
AFT Pharmaceuticals Ltd. engages in the development, licensing, and distribution of medical and pharmaceutical products. [ Read More ]
The intrinsic value of one AFT stock under the Base Case scenario is 5.08 NZD. Compared to the current market price of 3.09 NZD, AFT Pharmaceuticals Ltd is Undervalued by 39%.
Valuation Backtest
AFT Pharmaceuticals Ltd
Run backtest to discover the historical profit from buying and selling AFT stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
AFT Pharmaceuticals Ltd
| Current Assets | 95.1m |
| Cash & Short-Term Investments | 6.2m |
| Receivables | 33.4m |
| Other Current Assets | 55.5m |
| Non-Current Assets | 63.7m |
| PP&E | 4.1m |
| Intangibles | 49.7m |
| Other Non-Current Assets | 9.9m |
| Current Liabilities | 48.3m |
| Accounts Payable | 32.2m |
| Other Current Liabilities | 16.2m |
| Non-Current Liabilities | 36.6m |
| Long-Term Debt | 36.6m |
Earnings Waterfall
AFT Pharmaceuticals Ltd
|
Revenue
|
174.5m
NZD
|
|
Cost of Revenue
|
-94.3m
NZD
|
|
Gross Profit
|
80.2m
NZD
|
|
Operating Expenses
|
-60.8m
NZD
|
|
Operating Income
|
19.5m
NZD
|
|
Other Expenses
|
-8.4m
NZD
|
|
Net Income
|
11m
NZD
|
Free Cash Flow Analysis
AFT Pharmaceuticals Ltd
AFT Profitability Score
Profitability Due Diligence
AFT Pharmaceuticals Ltd's profitability score is 59/100. The higher the profitability score, the more profitable the company is.
Score
AFT Pharmaceuticals Ltd's profitability score is 59/100. The higher the profitability score, the more profitable the company is.
AFT Solvency Score
Solvency Due Diligence
AFT Pharmaceuticals Ltd's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Score
AFT Pharmaceuticals Ltd's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AFT Price Targets Summary
AFT Pharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for AFT is 3.77 NZD with a low forecast of 2.83 NZD and a high forecast of 4.83 NZD.
Shareholder Return
AFT Price
AFT Pharmaceuticals Ltd
| Average Annual Return | 23.53% |
| Standard Deviation of Annual Returns | 47.07% |
| Max Drawdown | -48% |
| Market Capitalization | 324m NZD |
| Shares Outstanding | 104 866 260 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
AFT Pharmaceuticals Ltd. engages in the development, licensing, and distribution of medical and pharmaceutical products. The firm's segments include New Zealand, Australia, Asia and Rest of World. The firm's products include Crystaderm, Maxigesic, Coco-scalp, Maxiclear, RestoraNail and Myconail, among others. The firm's NasoSURF Nebuliser is in pilot scale production. The firm is focused on conducting clinical for Maxigesic oral dose forms. The firm is also conducting clinical trials of Maxigesic intravenous (IV). Maxigesic PE is a cold and flu variant. Its subsidiary, AFT Pharmaceuticals (AU) Pty Ltd, is engaged in distribution of pharmaceuticals in Australia. Its subsidiary, AFT Pharmaceuticals Singapore Pte Ltd, is engaged in the registration of pharmaceuticals in Singapore. Its subsidiary, AFT Pharmaceuticals (S.E. Asia) Sdn Bhd, is engaged in the distribution of pharmaceuticals in Malaysia.
Contact
IPO
Employees
Officers
The intrinsic value of one AFT stock under the Base Case scenario is 5.08 NZD.
Compared to the current market price of 3.09 NZD, AFT Pharmaceuticals Ltd is Undervalued by 39%.
You don't have any saved screeners yet
